Angiogenesis is regulated by the dynamic interaction between endothelial cells (ECs).Hippo-Yes-associated protein (YAP) signalling has emerged as a key pathway that controls organ size and tissue growth by mediating cell contact inhibition. However, the role of YAP in EC has not been defined yet. Here, we show expression of YAP in the developing front of mouse retinal vessels. YAP subcellular localization, phosphorylation and activity are regulated by VE-cadherin-mediated-EC contacts. This VE-cadherin-dependent YAP phosphorylation requires phosphoinositide 3-kinase-Akt activation. We further identify angiopoietin-2 (ANG-2) as a potential transcriptional target of YAP in regulating angiogenic activity of EC in vitro and in vivo. Overexpression of YAP-active form in EC enhances angiogenic sprouting, and this effect is blocked by ANG-2 depletion or soluble Tie-2 treatment. These findings implicate YAP as a critical regulator in angiogenesis and provide new insights into the mechanism coordinating junctional stability and angiogenic activation of ECs.

IntroductionAngiogenesis is a critical process in physiologic and pathologic conditions, including embryo development, wound healing, tumor progression, and inflammatory diseases. 1 Inflammation and angiogenesis are closely associated, and pathologic angiogenesis has been implicated in the development of chronic inflammatory diseases. Interplay between inflammation and angiogenesis is mediated largely by cytokines, chemokines, and growth factors. Some of these molecules, including vascular endothelial growth factor (VEGF), induce endothelial permeability, allowing the infiltration of leukocytes to inflammatory sites, resulting in tissue damage. 2 Interleukin-33 (IL-33) is a newly identified cytokine of the IL-1 family, which also includes the inflammatory cytokines IL-1␣, It has been shown to signal via ST2 receptor. 4 IL-33 expression is broadly detected in various tissues, including stomach, lung, spinal cord, brain, and skin, as well as in cells, including smooth muscle cells and epithelial cells lining bronchus and small airways. 4 Notably, IL-33 expression is induced by IL-1␤ and tumor necrosis factor-␣ (TNF-␣) in lung and dermal fibroblast and, to a lesser extent, by macrophage activation. 4 IL-33 treatment has been shown to induce T-helper (Th) type 2 responses in mice as indicated by an increase in Th2 cytokine production and serum immunoglobulin. Systemic treatment of mice with IL-33 results in pathologic changes in the lung and the digestive tract. In the lung, vascular changes accompanied with eosinophilic and mononuclear infiltrates were observed in small muscular arteries. 4 Recently, functions of IL-33 in cardiovascular diseases have been reported. For example, IL-33 can reduce the development of atherosclerosis in apolipoprotein E Ϫ/Ϫ mice on a high-fat diet. 5 Furthermore, IL-33/ST2 complexes also have been shown to activate cardioprotective signaling pathways. 6 IL-33 is produced as a 30-kDa precursor protein that is cleaved in vitro by caspase-1, releasing the mature 18-kDa form. 4 Upon binding to the ST2 receptor, IL-33 promotes the activation of nuclear factor (NF)-B and mitogen-activated protein kinase (MAPK), leading to increased transcription of Th2 cytokines. 4 The ST2 receptor, a member of IL-1 receptor family, has long been known as an orphan receptor. Despite its structural and functional similarity to IL-1 receptor family, the ST2 receptor does not bind to IL-1␣ or IL-1␤ or other members of the IL-1 family. Two isoforms, a soluble (sST2) and a membrane bound form (ST2L), are produced through differential mRNA processing. 7,8 ST2L is expressed mainly in mast cells and Th2 cells. 7,8 Both ST2 forms also are expressed in freshly isolated human umbilical vein endothelial cells (HUVECs), and they are up-regulated by proinflammatory stimuli such as TNF, IL-1␣, and IL-1␤. 9 Nitric oxide (NO) production in endothelial cells (ECs) is transiently regulated by multiple inflammatory angiogenic factors such as VEGF and angiopoietin-1. 10,11 NO, in turn, modulates the angiogenic function of these ...

No abstract

No abstract

Nitric oxide (NO), synthesized from L-arginine by NO synthases, is a small, lipophilic, diffusible, highly reactive molecule with dichotomous regulatory roles in many biological events under physiological and pathological conditions. NO can promote apoptosis (pro-apoptosis) in some cells, whereas it inhibits apoptosis (anti-apoptosis) in other cells. This complexity is a consequence of the rate of NO production and the interaction with biological molecules such as metal ion, thiol, protein tyrosine, and reactive oxygen species. Long-lasting overproduction of NO acts as a pro-apoptotic modulator, activating caspase family proteases through the release of mitochondrial cytochrome c into cytosol, up-regulation of the p53 expression, and alterations in the expression of apoptosis-associated proteins, including the Bcl-2 family. However, low or physiological concentrations of NO prevent cells from apoptosis that is induced by the trophic factor withdrawal, Fas, TNFalpha/ActD, and LPS. The anti-apoptotic mechanism is understood on the basis of gene transcription of protective proteins. These include: heat shock protein, hemeoxygenase, or cyclooxygenase-2 and direct inhibition of the apoptotic executive effectors caspase family protease by S-nitrosylation of the cysteine thiol group in their catalytic site in a cell specific way. Our current understanding of the mechanisms by which NO exerts both pro- and anti-apototic action is discussed in this review article.